Concurrently, Moody’s assigned its “A3” rating on SGHS’ proposed $104 million series 2017 bonds.
The downgrade is a result of several factors, including SGHS’ heavy debt burden, high leverage position and weakened operating performance. Moody’s also acknowledged the health system’s dominant market position and maintenance of liquidity measures in recent years.
The outlook is negative, reflecting the health system’s decline in operating performance.
More articles on healthcare finance:
Why Harvard’s $37B endowment is at risk of mediocrity
12 hospitals seeking RCM talent
Irving family presents record $700M bequest to NewYork-Presbyterian, Columbia University
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
